Open AccessA plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma
Author(s) -
Daniel J. Olson,
Jason J. Luke
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2022-0121
Subject(s) - ipilimumab , pembrolizumab , medicine , melanoma , oncology , nivolumab , cancer , immunotherapy , dermatology , cancer research
In this article, we discuss the results of our clinical study that looked at the use of two immunotherapy drugs for the treatment of advanced melanoma. Melanoma is considered advanced when it is no longer curable with surgery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom